LONDON: AstraZeneca Plc, the UK’s second-largest drugmaker, raised its earnings and sales forecast for the full year as demand for its Nexium antacid and Crestor heart drug beat estimates.
Core earnings per share, a measure used by the company that excludes some costs, will increase by a mid- to high single- digit percentage from a year earlier, the London-based company said in a statement. Revenue will grow by a low single-digit percentage, it said. Third-quarter profit also beat estimates. Core earnings fell to US$1.03 a share in the quarter from US$1.05 a share a year earlier.
Already a subscriber? Log in.
Win a prize this Mother's Day by subscribing to our annual plan now! T&C applies.
Cancel anytime. No ads. Auto-renewal. Unlimited access to the web and app. Personalised features. Members rewards.
Follow us on our official WhatsApp channel for breaking news alerts and key updates!
